Bleakley Financial Group LLC Acquires Shares of 13,246 Privia Health Group, Inc. (NASDAQ:PRVA)

Bleakley Financial Group LLC purchased a new stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 13,246 shares of the company’s stock, valued at approximately $305,000.

Several other hedge funds and other institutional investors also recently modified their holdings of PRVA. Tower Research Capital LLC TRC increased its position in shares of Privia Health Group by 171.1% during the first quarter. Tower Research Capital LLC TRC now owns 1,578 shares of the company’s stock valued at $44,000 after buying an additional 996 shares during the period. Point72 Hong Kong Ltd purchased a new position in shares of Privia Health Group during the first quarter valued at about $47,000. Neo Ivy Capital Management purchased a new position in shares of Privia Health Group during the second quarter valued at about $53,000. Benjamin Edwards Inc. purchased a new position in shares of Privia Health Group during the second quarter valued at about $58,000. Finally, Jefferies Financial Group Inc. purchased a new position in shares of Privia Health Group during the fourth quarter valued at about $72,000. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Privia Health Group Stock Performance

Shares of NASDAQ PRVA opened at $18.35 on Tuesday. The company has a market cap of $2.18 billion, a PE ratio of 96.58, a P/E/G ratio of 2.53 and a beta of 0.81. The firm’s 50 day moving average price is $20.29 and its 200-day moving average price is $21.52. Privia Health Group, Inc. has a 52-week low of $17.54 and a 52-week high of $30.15.

Privia Health Group (NASDAQ:PRVA) last issued its quarterly earnings data on Tuesday, February 27th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The company had revenue of $440.80 million for the quarter, compared to the consensus estimate of $425.81 million. Privia Health Group had a net margin of 1.39% and a return on equity of 3.97%. The firm’s revenue for the quarter was up 21.0% on a year-over-year basis. During the same quarter last year, the company earned $0.14 EPS. On average, analysts forecast that Privia Health Group, Inc. will post 0.26 earnings per share for the current fiscal year.

Insider Activity at Privia Health Group

In related news, CFO David Mountcastle sold 3,933 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $17.77, for a total transaction of $69,889.41. Following the transaction, the chief financial officer now owns 262,279 shares in the company, valued at $4,660,697.83. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Privia Health Group news, Director William M. Sullivan sold 9,951 shares of the stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $23.03, for a total value of $229,171.53. Following the transaction, the director now directly owns 5,464,533 shares in the company, valued at $125,848,194.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO David Mountcastle sold 3,933 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $17.77, for a total transaction of $69,889.41. Following the completion of the transaction, the chief financial officer now owns 262,279 shares in the company, valued at $4,660,697.83. The disclosure for this sale can be found here. 14.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on PRVA. UBS Group reduced their price target on shares of Privia Health Group from $31.00 to $29.00 and set a “buy” rating on the stock in a research report on Friday, March 1st. Barclays assumed coverage on shares of Privia Health Group in a report on Wednesday, March 6th. They issued an “equal weight” rating and a $22.00 price objective on the stock. TD Cowen cut their price objective on shares of Privia Health Group from $30.00 to $26.00 and set an “outperform” rating on the stock in a report on Friday, March 1st. Canaccord Genuity Group cut their price objective on shares of Privia Health Group from $41.00 to $37.00 and set a “buy” rating on the stock in a report on Tuesday, March 19th. Finally, Jefferies Financial Group assumed coverage on shares of Privia Health Group in a report on Monday, February 26th. They issued a “buy” rating and a $25.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $28.18.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.